Biodesix Inc. (BDSX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?
Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?
The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference
Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy.
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?
Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet
The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
Biodesix Q2 Earnings Call Highlights
Biodesix NASDAQ: BDSX reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its commercial organization.
Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $1.6 per share a year ago.
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year.
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
